Literature DB >> 22644880

When is irritable bowel syndrome not irritable bowel syndrome? Diagnosis and treatment of chronic functional abdominal pain.

Madhusudan Grover1.   

Abstract

Functional abdominal pain syndrome (FAPS) is a distinct chronic gastrointestinal (GI) pain disorder characterized by the presence of constant or frequently recurring abdominal pain that is not associated with eating, change in bowel habits, or menstrual periods. The pain experience in FAPS is predominantly centrally driven as compared to other chronic painful GI conditions such as inflammatory bowel disease and chronic pancreatitis where peripherally acting factors play a major role in driving the pain. Psychosocial factors are often integrally associated with the disorder and can pose significant challenges to evaluation and treatment. Patients suffer from considerable loss of function, which can drive health care utilization. Treatment options are limited at best with most therapeutic regimens extrapolated from pain management of other functional GI disorders and chronic pain conditions. A comprehensive approach to management using a biopsychosocial construct and collaboration with pain specialists and psychiatry is most beneficial to the management of this disorder.

Entities:  

Mesh:

Year:  2012        PMID: 22644880     DOI: 10.1007/s11894-012-0270-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  41 in total

1.  Increased wind-up to heat pain in women with a childhood history of functional abdominal pain.

Authors:  Christine M Dengler-Crish; Stephen Bruehl; Lynn S Walker
Journal:  Pain       Date:  2011-02-01       Impact factor: 6.961

2.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

Review 3.  Functional abdominal pain syndrome.

Authors:  Ray E Clouse; Emeran A Mayer; Qasim Aziz; Douglas A Drossman; Dan L Dumitrascu; Hubert Mönnikes; Bruce D Naliboff
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

4.  Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation.

Authors:  B D Naliboff; S W Derbyshire; J Munakata; S Berman; M Mandelkern; L Chang; E A Mayer
Journal:  Psychosom Med       Date:  2001 May-Jun       Impact factor: 4.312

5.  Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome.

Authors:  G F Longstreth; D B Preskill; L Youkeles
Journal:  Dig Dis Sci       Date:  1990-10       Impact factor: 3.199

Review 6.  Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders.

Authors:  Madhusudan Grover; Douglas A Drossman
Journal:  Gastrointest Endosc Clin N Am       Date:  2009-01

7.  Development of abdominal pain and IBS following gynecological surgery: a prospective, controlled study.

Authors:  Ami D Sperber; Carolyn Blank Morris; Lev Greemberg; Shrikant I Bangdiwala; David Goldstein; Eyal Sheiner; Yefim Rusabrov; Yuming Hu; Miriam Katz; Tami Freud; Anat Neville; Douglas A Drossman
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

8.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

Review 9.  Sexual and physical abuse and gastrointestinal illness. Review and recommendations.

Authors:  D A Drossman; N J Talley; J Leserman; K W Olden; M A Barreiro
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

Review 10.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.